Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
Status:
Terminated
Trial end date:
2016-10-27
Target enrollment:
Participant gender:
Summary
The investigators propose to assess the efficacy, progression-free survival, and adverse
events of pacritinib in patients with refractory colorectal cancer.